Both Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) and Histogenics Corporation (NASDAQ:HSGX) are Biotechnology companies, competing one another. We will contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Corvus Pharmaceuticals Inc.||4||0.00||N/A||-1.52||0.00|
We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Corvus Pharmaceuticals Inc. and Histogenics Corporation.
Table 2 provides the return on equity, return on assets and net margins of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Corvus Pharmaceuticals Inc.||0.00%||-38.7%||-35.7%|
Risk and Volatility
Corvus Pharmaceuticals Inc. has a 1.1 beta, while its volatility is 10.00%, thus making it more volatile than Standard and Poor’s 500. Histogenics Corporation on the other hand, has 3.29 beta which makes it 229.00% more volatile compared to Standard and Poor’s 500.
Corvus Pharmaceuticals Inc. has a Current Ratio of 12.4 and a Quick Ratio of 12.4. Competitively, Histogenics Corporation’s Current Ratio is 3.5 and has 3.5 Quick Ratio. Corvus Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Histogenics Corporation.
Insider & Institutional Ownership
Corvus Pharmaceuticals Inc. and Histogenics Corporation has shares held by institutional investors as follows: 84.9% and 13%. About 5.09% of Corvus Pharmaceuticals Inc.’s share are held by insiders. Competitively, insiders own roughly 6% of Histogenics Corporation’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Corvus Pharmaceuticals Inc.||-17.34%||-5.78%||-7.35%||0.26%||-59.65%||6.54%|
For the past year Corvus Pharmaceuticals Inc. was less bullish than Histogenics Corporation.
On 5 of the 7 factors Histogenics Corporation beats Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.